Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCERNA: Zolbetuximab + pembrolizumab + chemotherapy vs placebo + pembrolizumab + chemotherapy in first-line CLDN18.2-positive, PD-L1-positive, HER2-negative gastric/GEJ cancer
jRCT2031250021Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall survival. Started May 2025; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250021.